Aummune

Executive Summary

Aummune is a clinical-stage Israeli biotechnology company pioneering a novel tri-functional oligonucleotide platform for cancer immunotherapy. Its patient-specific drugs combine a tumor-targeting aptamer, a CpG bridge, and a T-cell engaging strand to simultaneously kill solid tumor cells and activate both innate and adaptive immunity. This synergistic approach aims to overcome the limitations of conventional immunotherapies, which often fail to generate robust and durable responses in solid tumors. Founded in 2020 and headquartered in Tel Aviv, Aummune has advanced its lead candidate into Phase 1 clinical trials, demonstrating early promise in preclinical models. The company's platform is highly versatile, enabling rapid customization for different tumor types, and has the potential to address a broad range of oncology indications. Aummune operates in the competitive but rapidly evolving oncology space, where innovative immunotherapies are in high demand. With a focus on personalized medicine, the company is well-positioned to capture significant market share if its clinical data continue to show favorable safety and efficacy. The upcoming milestones are critical for validating its technology and securing the next round of financing to advance its pipeline.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 safety and efficacy data readout for lead candidate55% success
• Q2 2027FDA clearance of IND for a second indication60% success
• Q1 2027Series B financing or strategic partnership announcement50% success